Skip to main content

Advertisement

SpringerLink
Log in

A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the study was to improve abdominal tumor detection by use of a dual radiologic contrast protocol.

Procedures

eXia160® (Benitio international) was mixed with 2-deoxy-2-[18F]fluoro-d-glucose or 3′-[18F]fluoro-3′-deoxythymidine for intravenous (IV) injections. Omnipaque® 300 (GE healthcare) was used for intraperitoneal (IP) injections. Positron emission tomography/computed tomography (PET/CT) scans were acquired on a Siemens Biograph® equipped with point spread function reconstruction. The optimal concentration and injection schedule of IP contrast agent was studied in 12 mice. The impact of IP contrast media on PET quantitative accuracy was investigated by phantom studies and by imaging six mice before and after IP injection of Omnipaque®. The impact of a dual contrast media protocol on tumor delineation and quantitation was evaluated in 15 tumor-bearing mice using ex vivo counting as the reference.

Results

The optimal sequence was a mixture of tracer plus IV contrast agent followed by 1 mL of IP contrast agent (20 mg iodine/mL) administered 10 min before PET/CT acquisition. Phantom studies showed that the use of a 20-mg iodine/mL concentration of Omnipaque® led to a 4.8% overestimation of radioactivity concentration, as compared to saline. This was confirmed by animal studies that demonstrated a 4.3% overestimation. Tumor detection was excellent and correlation between PET/CT quantitative data and ex vivo counting was good (r 2 = 0.91, slope = 0.7).

Conclusions

A dual radiologic contrast protocol is useful in PET/CT scanning of mice bearing abdominal tumors. Contrast agents used in this manner lead to a small but acceptable overestimation of quantitative PET data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LY, Croce CM (2007) Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res 67(12):5606–5610

    Article  PubMed  CAS  Google Scholar 

  2. Fujishita T, Doi Y, Sonoshita M et al (2004) Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice. Br J Cancer 91(8):1571–1574

    PubMed  CAS  Google Scholar 

  3. Kizaka-Kondoh S, Itasaka S, Zeng L et al (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15:3433–3441

    Article  PubMed  CAS  Google Scholar 

  4. Yi XF, Yuan ST, Lu LJ, Ding J, Feng YJ (2005) A clinically relevant orthotopic implantation nude mouse model of human epithelial ovarian cancer—based on consecutive observation. Int J Gynecol Cancer 15(5):850–855

    Article  PubMed  Google Scholar 

  5. Choquet P, Calon A, Breton E et al (2007) Multiple-contrast X-ray micro-CT visualization of colon malformations and tumours in situ in living mice. C R Biol 330(11):821–827

    Article  PubMed  Google Scholar 

  6. Graham KC, Detombe SA, MacKenzie LT et al (2008) Contrast-enhanced microcomputed tomography using intraperitoneal contrast injection for the assessment of tumor-burden in liver metastasis models. Invest Radiol 43(7):488–495

    Article  PubMed  Google Scholar 

  7. Willekens I, Lahoutte T, Buls N et al (2009) Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC. Mol Imaging Biol 11(2):128–135

    Article  PubMed  Google Scholar 

  8. Almajdub M, Nejjari M, Poncet G et al (2007) In vivo high-resolution X-ray microtomography for liver and spleen tumor assessment in mice. Contrast Media Mol Imaging 2(2):88–93

    Article  PubMed  CAS  Google Scholar 

  9. Suckow CE, Stout DB (2008) MicroCT liver contrast agent enhancement over time, dose, and mouse strain. Mol Imaging Biol 10(2):114–120

    Article  PubMed  Google Scholar 

  10. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70

    Article  PubMed  CAS  Google Scholar 

  11. Pichler BJ, Wehrl HF, Judenhofer MS (2008) Latest advances in molecular imaging instrumentation. J Nucl Med 49(Suppl 2):5S–23S

    Article  PubMed  Google Scholar 

  12. ` Antoch G, Jentzen W, Freudenberg LS et al (2003) Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 38(12):784–789

    PubMed  CAS  Google Scholar 

  13. Serdons K, Verbruggen A, Bormans G (2008) The presence of ethanol in radiopharmaceutical injections. J Nucl Med 49(12):2071

    Article  PubMed  Google Scholar 

  14. Cohade C, Osman M, Nakamoto Y et al (2003) Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 44(3):412–416

    PubMed  Google Scholar 

  15. Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C (2003) Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 44(5):732–738

    PubMed  Google Scholar 

  16. Aide N, Desmonts C, Beauregard JM et al (2010) High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. Eur J Nucl Med Mol Imaging 37:991–1001

    Article  PubMed  Google Scholar 

  17. Denoyer D, Greguric I, Roselt P et al (2010) High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med 51(3):441–447

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported and by a Fellowship from the Fondation de France, and by a grant from the French Ligue contre le cancer, Comité du Calvados. The authors thank Emily Hong, Jason Callahan, David Binns and Mark Scalzo for their help during animals PET acquisitions and ex vivo counting and the animal technologists and research assistants (Kerry Ardley, Rachel Walker, Susan Jackson, Jeannette Valentan, Ekaterina Bogatyreva and Laura Kirby) from the Centre for Molecular Imaging for animal care and tracer injections. Dr. Aide is indebted to Dr. Lerouge for her continuous support during this work.

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Bioticla Team, EA 1772, IFR 146 ICORE, GRECAN, François Baclesse Cancer Centre and Caen University, Caen, France

    Nicolas Aide

  2. PET Centre, Caen University Hospital and François Baclesse Cancer Centre, Caen, France

    Nicolas Aide

  3. Centre for Molecular Imaging, Peter MacCallum Cancer Centre, East Melbourne, Australia

    Nicolas Aide, Kathryn Kinross, Jean-Mathieu Beauregard, Oliver Neels, Peter Roselt, Donna Dorow & Rodney J. Hicks

  4. Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia

    Kathryn Kinross, Titaina Potdevin, Donna Dorow, Carleen Cullinane & Rodney J. Hicks

  5. The Department of Medicine, The University of Melbourne, Parkville, Australia

    Rodney J. Hicks

  6. Nuclear Medicine Department, Centre François Baclesse, Avenue Général Harris, 14076, Caen cedex 5, France

    Nicolas Aide

Authors
  1. Nicolas Aide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn Kinross
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Mathieu Beauregard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliver Neels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Titaina Potdevin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Roselt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Donna Dorow
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carleen Cullinane
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rodney J. Hicks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Aide.

Additional information

A dual radiologic contrast protocol, which includes a mixture of tracer plus long-lasting intravenous contrast agent followed by intraperitoneal contrast agent, is described that provides better anatomical separation and delineation of abdominal tumors for PET/CT scanning of mice.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aide, N., Kinross, K., Beauregard, JM. et al. A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors. Mol Imaging Biol 13, 518–525 (2011). https://doi.org/10.1007/s11307-010-0378-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-010-0378-x

Key words

Search

Navigation